We report the first case of extensive involvement of isolated intracranial Rosai-Dorfman's disease (RDD) in a child. Our case is unique because it presents with involvement of the middle cranial fossa, cavernous sinus, pituitary gland, orbit, ethmoid and sphenoid sinuses. Previous cases of intracranial RDD in children have reported separate involvement of cavernous sinus, suprasellar region, and frontal and petroclival regions. Involvement of the pituitary gland has so far not been reported. A 14-year-old male presented with a medical history of loss of vision, raised erythrocyte sedimentation rate (ESR), and abnormal prolactin and cortisol levels. Radiologically the diagnosis was meningioma. The histopathological diagnosis was RDD with emperipolesis and S-100 positivity. RDD is a histiocytic proliferation of unknown aetiology, which commonly affects lymph nodes. Uncommonly it involves the extranodal sites and rarely the central nervous system (CNS). 80 cases of RDD involving CNS have been reported in the literature, and only 5 were in children. Although the definitive diagnosis of RDD disease is based on the histopathology report, it should be included in the differentials of a lesion mimicking meningioma especially in children.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3473498 | PMC |
http://dx.doi.org/10.1259/bjr/15772106 | DOI Listing |
BMC Infect Dis
December 2024
Central Laboratory, Chongqing Public Health Medical Centre, Chongqing, China.
Background: In acquired immunodeficiency syndrome patients, Talaromyces marneffei infections are mostly disseminated and may involve the skin, mucosa, respiratory system, digestive system, lymphatic system, and as some reports indicate, the nervous system. Mp1p, a cell wall-specific polysaccharide in Talaromyces marneffei, is used for laboratory diagnosis of Talaromyces marneffei in blood and urine samples. However, Cerebrospinal fluid Mp1p diagnosis of Talaromyces marneffei central nervous system infection has not been reported.
View Article and Find Full Text PDFBiomed Phys Eng Express
December 2024
Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Dr, Stanford, California, 94305-6104, UNITED STATES.
Single-isocenter multitarget (SIMT) stereotactic-radiosurgery (SRS) has recently emerged as a powerful treatment regimen for intracranial tumors. With high specificity, SIMT SRS allows for rapid, high-dose delivery while maintaining integrity of adjacent healthy tissues and minimizing neurocognitive damage to patients. Highly robust and accurate quality assurance (QA) tests are critical to minimize off-targets and damage to surrounding healthy tissues.
View Article and Find Full Text PDFJ Neurosurg Sci
December 2024
NeuroCritical Care Unit, Department of Anesthesia, Critical Care and Emergency Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
Background: One in four patients with moderate to severe traumatic brain injury (TBI) also has other body district injuries (OBD). The impact of OBD on mortality and disability is debated. This study compared outcomes of TBI patients with polytrauma (p-TBI) versus isolated TBI (alone-TBI) and identified outcome determinants, focusing on survival time and prognosis.
View Article and Find Full Text PDFZh Vopr Neirokhir Im N N Burdenko
December 2024
Burdenko Neurosurgical Center, Moscow, Russia.
Unlabelled: Autologous blood obtained during hardware reinfusion can be bacterially contaminated with skin microflora in most cases (up to 90%) regardless of the area of surgical intervention. Increased volume of washing solution for red blood cell management, white blood cell filtration and X-ray irradiation do not always provide complete decontamination.
Objective: To analyze the effectiveness of adding cefuroxime to extracorporeal circuit during hardware blood reinfusion.
J Int Adv Otol
November 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!